Johnson & Johnson

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, ABIO, MODN

Retrieved on: 
Monday, April 15, 2024
Sale, Advertising, Johnson & Johnson, Model N, Shock wave, ARCA, Vista Equity Partners, Aimco, Fraud, Security (finance)

If you are a Shockwave shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Shockwave shareholder, click here to learn more about your rights and options .
  • If you are an Apartment Income shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN), ARCA biopharma, Inc. (Nasdaq - ABIO)

Retrieved on: 
Monday, April 15, 2024
Model, Vista, AIR, JNJ, Johnson & Johnson, ARCA, Model N, Brodsky, Vista Equity Partners, Security (finance)

BALA CYNWYD, Pa., April 15, 2024 (GLOBE NEWSWIRE) --  Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., April 15, 2024 (GLOBE NEWSWIRE) --  Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Merger Agreement, Shockwave will be acquired by Johnson & Johnson (NYSE - JNJ).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer

Retrieved on: 
Thursday, May 2, 2024
Communications, Health, Manufacturing, Other Health, Other Manufacturing, Public Relations, Investor Relations, Advisory Council, University, Bangladesh Technical Education Board, Laboratory, Johnson & Johnson, Trustee, Kodak, Abbott Laboratories, Ortho Clinical Diagnostics, Mechanical, Growth, General Motors, Transfusion medicine, Multimedia, QuidelOrtho, MBA, Management

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company’s Board of Directors (the “Board”) has appointed Brian J. Blaser as President and Chief Executive Officer (“CEO”) effective May 6.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company’s Board of Directors (the “Board”) has appointed Brian J. Blaser as President and Chief Executive Officer (“CEO”) effective May 6.
  • View the full release here: https://www.businesswire.com/news/home/20240502548327/en/
    “We are excited to welcome Brian as our new president, CEO and director,” said Kenneth F. Buechler, Ph.D., Chairman of the Board.
  • “I am honored and excited to join QuidelOrtho as president and CEO during this pivotal point in the Company’s journey.
  • The Company’s commitment to customer service and its dedication to improving healthcare outcomes align closely with my own values,” said Brian J. Blaser, President and CEO, QuidelOrtho.

Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

Retrieved on: 
Wednesday, May 1, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Mesothelioma, Imerys, Safety, State, JNJ, Bankruptcy, Johnson & Johnson, MDL, Science, Worldwide, Cyprus Mines Corporation, Talc, LLT, Ovarian cancer, Insurance

“The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson.

Key Points: 
  • “The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson.
  • The remaining pending personal injury lawsuits relate to mesothelioma and will be addressed outside of the Plan.
  • The State consumer protection claims will also be addressed outside the Plan; the Company already has agreements in principle to do so.
  • In light of those risks, counsel representing the overwhelming majority of current ovarian claimants assisted in the development and support the Plan.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
Wednesday, May 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

Retrieved on: 
Wednesday, May 1, 2024
Health, Medical Devices, Consumer, Women, Surgery, Health Technology, General Health, Xavier University, FDA, University, ESTA, American Cyanamid, Woman, Regenerative medicine, Breast augmentation, Johnson & Johnson, U.S. FDA, Science, Marketing, MBA, PMA, Organization

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.
  • “Jeff is the ideal person to introduce Motiva to the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs.
  • Mr. Ehrhardt was most recently General Manager for Plastic Surgery & Regenerative Medicine at Allergan Aesthetics.
  • "Joining Establishment Labs is in many ways the culmination of the last 25 years of my career,” said Jeff Ehrhardt.

insitro Hires AI and Machine Learning Visionary, Emily Fox, Ph.D., as Senior Vice President of AI/ML

Retrieved on: 
Tuesday, April 30, 2024
Data Management, Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Health Technology, Data Analytics, Software, Artificial Intelligence, Clinical Trials, Stanford University, University, Genetics, Scientist, Genomics, Ecosystem, Computer science, Chan Zuckerberg Biohub, Sloan Research Fellowship, Daphne, Johnson & Johnson, Eli Lilly, Machine learning, Neuroscience, Computational biology, Research, NSF, Amazon, Data science, Department of Statistics, Translation, Sequoia, Data collection, Biology, Methodology, ONR, Apple, Drug development, Drug discovery, Knowledge, Engineering, Seattle Coronavirus Assessment Network, MIT, Medical device

insitro, a machine learning-powered drug discovery and development company, today announced the appointment of Emily Fox, Ph.D., as senior vice president of AI/machine learning.

Key Points: 
  • insitro, a machine learning-powered drug discovery and development company, today announced the appointment of Emily Fox, Ph.D., as senior vice president of AI/machine learning.
  • “Her groundbreaking work in machine learning, alongside her track record in translating research into impactful applications in healthcare, aligns perfectly with our mission to revolutionize drug discovery through data-driven approaches.
  • With Emily joining insitro, their combined efforts in leveraging AI for biology discovery and drug development are set to revolutionize the field.
  • It’s collaborations like these that highlight the power of diverse minds in AI, driving not just technological progress, but societal betterment as well.”

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HRT, ADTH, SWAV, AIRC

Retrieved on: 
Thursday, April 11, 2024
Sale, HireRight, Advertising, Johnson & Johnson, Shock wave, General Atlantic, Aimco, Fraud, Security (finance)

If you are a HireRight shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a HireRight shareholder, click here to learn more about your rights and options .
  • If you are an AdTheorent shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SWAV Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Shockwave Medical to Johnson & Johnson

Retrieved on: 
Wednesday, April 10, 2024
Sale, Johnson & Johnson, TipRanks, Wohl

MONSEY, N.Y., April 10, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $335.00 per share in cash for which Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) has agreed to be sold to Johnson & Johnson.

Key Points: 
  • MONSEY, N.Y., April 10, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $335.00 per share in cash for which Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) has agreed to be sold to Johnson & Johnson.
  • The sales price is below the price target for Shockwave of at least one Wall Street analyst (source: TipRanks).
  • On April 5, 2024, Shockwave announced that it had agreed to be sold to Johnson & Johnson for $335.00 per share in cash.
  • “We are investigating whether the Shockwave Board of Directors acted in the best interests of Shockwave shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter.

AACN’s New Web Resource Focuses on Preparing Nurses with Essential Well-Being and Leadership Competencies

Retrieved on: 
Thursday, April 25, 2024
Nursing, General Health, Health, Other Education, Continuing, University, Education, Training, Well, Learning, Essential, Teaching, School, Experiential learning, Emotional intelligence, Johnson & Johnson, Research, Curriculum, Mental health, Professional, Faculty, Workforce, Student, AACN, Leadership development

Moving to implement the Essentials presents a unique opportunity for schools of nursing to infuse innovation into curriculum to better prepare nurses to thrive across practice settings.

Key Points: 
  • Moving to implement the Essentials presents a unique opportunity for schools of nursing to infuse innovation into curriculum to better prepare nurses to thrive across practice settings.
  • The latest standards call for preparing nurses with specific competencies related to leadership development, professionalism, emotional intelligence, wellness, and resilience.
  • In March 2022, AACN launched an initiative titled A Competency-Based Approach to Leadership Development and Resilience for Student Nurses to identify learning experiences that foster personal health, well-being, and leadership skills in graduates of baccalaureate nursing programs.
  • As AACN continues to champion innovative approaches to nursing education, we encourage faculty to explore this valuable resource on our website .